Polygenic Score (PGS) ID: PGS003378

Predicted Trait
Reported Trait Prostate-specific antigen (PSA) levels
Mapped Trait(s) prostate specific antigen amount (OBA_2050200)
Additional Trait Information log(PSA) in men without prostate cancer
Released in PGS Catalog: June 1, 2023
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name PSA_PGS_128
Development Method
Name Clumping and Thresholding (C+T)
Parameters Clumping: p-value<5E-08 and LD r2<0.01 within 10Mb in 1000G EUR (additional step: check for LD r2<0.05 in 1000G ALL)
Variants
Original Genome Build GRCh37
Number of Variants 128
Effect Weight Type NR
PGS Source
PGS Catalog Publication (PGP) ID PGP000412
Citation (link to publication) Kachuri L et al. Nat Med (2023)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 89.6%
African: 3.7%
East Asian: 3.5%
Hispanic or Latin American: 3.2%
95,768 individuals (100%)
PGS Evaluation
African: 37.5%
European: 25%
Multi-ancestry (including European): 25%
  • European
  • African
  • Not Reported
East Asian: 12.5%
8 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
85,824 individuals,
100.0 % Male samples
European BioVU, GERA, MDC, PLCO, UKB
3,509 individuals,
100.0 % Male samples
African American or Afro-Caribbean BioVU, GERA, PLCO
3,337 individuals,
100.0 % Male samples
East Asian GERA, PLCO
3,098 individuals,
100.0 % Male samples
Hispanic or Latin American GERA, PLCO

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM016240 PSS010066|
European Ancestry|
5,725 individuals
PGP000412 |
Kachuri L et al. Nat Med (2023)
Reported Trait: Baseline/pre-randomization log(PSA) β: 0.169 Partial R2 (%, variation explained by the PGS only): 7.33 Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1
PPM016241 PSS010073|
Multi-ancestry (including European)|
25,917 individuals
PGP000412 |
Kachuri L et al. Nat Med (2023)
Reported Trait: Baseline/pre-randomization log(PSA) β: 0.207 Partial R2 (%, variation explained by the PGS only): 8.0 Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1
PPM016242 PSS010072|
European Ancestry|
22,173 individuals
PGP000412 |
Kachuri L et al. Nat Med (2023)
Reported Trait: Baseline/pre-randomization log(PSA) β: 0.213 Partial R2 (%, variation explained by the PGS only): 8.78 Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1
PPM016243 PSS010070|
African Ancestry|
2,936 individuals
PGP000412 |
Kachuri L et al. Nat Med (2023)
Reported Trait: Baseline/pre-randomization log(PSA) β: 0.154 Partial R2 (%, variation explained by the PGS only): 3.36 Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1
PPM016244 PSS010068|
African Ancestry|
1,173 individuals
PGP000412 |
Kachuri L et al. Nat Med (2023)
Reported Trait: Baseline/pre-randomization log(PSA) β: 0.163 Partial R2 (%, variation explained by the PGS only): 3.45 Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1
PPM016245 PSS010069|
African Ancestry|
1,763 individuals
PGP000412 |
Kachuri L et al. Nat Med (2023)
Reported Trait: Baseline/pre-randomization log(PSA) β: 0.146 Partial R2 (%, variation explained by the PGS only): 3.32 Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1
PPM016246 PSS010071|
East Asian Ancestry|
257 individuals
PGP000412 |
Kachuri L et al. Nat Med (2023)
Reported Trait: Baseline/pre-randomization log(PSA) β: 0.136 Partial R2 (%, variation explained by the PGS only): 2.45 Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1
PPM016239 PSS010067|
Multi-ancestry (including European)|
5,883 individuals
PGP000412 |
Kachuri L et al. Nat Med (2023)
Reported Trait: Baseline/pre-randomization log(PSA) β: 0.168 Partial R2 (%, variation explained by the PGS only): 7.16 Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS010066 Baseline/pre-randomization PSA in men without prostate cancer 5,725 individuals,
100.0 % Male samples
European
(Predominantly European)
European (EUR) ancestry cluster based on SNPWEIGHTS score >=0.80; median EUR = 0.998; mean EUR = 0.991 PCPT Minimum enrollment age was 55 years with serum PSA <= 3 ng/mL
PSS010067 Baseline/pre-randomization PSA in men without prostate cancer 5,883 individuals,
100.0 % Male samples
European, Not reported Multi-ancestry pooled sample PCPT Minimum enrollment age was 55 years with serum PSA <= 3 ng/mL
PSS010068 Baseline/pre-randomization PSA in men without prostate cancer 1,173 individuals,
100.0 % Male samples
African American or Afro-Caribbean
(Predominantly West African)
West African (AFR) ancestry cluster based on SNPWEIGHTS score >=0.80; median AFR = 0.855; mean AFR = 0.861 SELECT Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL
PSS010069 Baseline/pre-randomization PSA in men without prostate cancer 1,763 individuals,
100.0 % Male samples
African American or Afro-Caribbean
(West African admixed)
0.20 < West African (AFR) ancestry score <0.80 based on SNPWEIGHTS; median AFR = 0.673; mean AFR = 0.602 SELECT Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL
PSS010070 Baseline/pre-randomization PSA in men without prostate cancer 2,936 individuals,
100.0 % Male samples
African American or Afro-Caribbean
(West African admixed)
West African (AFR) ancestry score >0.20 based on SNPWEIGHTS; median AFR = 0.765; mean AFR = 0.705 SELECT Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL
PSS010071 Baseline/pre-randomization PSA in men without prostate cancer 257 individuals,
100.0 % Male samples
East Asian
(Predominantly East Asian)
East Asian (EAS) ancestry cluster based on SNPWEIGHTS score >=0.80; median EAS = 0.978; mean EAS = 0.972 SELECT Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL
PSS010072 Baseline/pre-randomization PSA in men without prostate cancer 22,173 individuals,
100.0 % Male samples
European
(Predominantly European)
European (EUR) ancestry cluster based on SNPWEIGHTS score >=0.80; median EUR = 0.995; mean EUR = 0.986 SELECT Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL
PSS010073 Baseline/pre-randomization PSA in men without prostate cancer 25,917 individuals,
100.0 % Male samples
European, African American or Afro-Caribbean Multi-ancestry pooled sample SELECT Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL